腺三酸盐通过增加Aβ动态来诱导粉样β的无形聚合,从而增加Aβ动态
Masahiro Kuramochi1, Momoka Nakamura2, Hiroto Takahashi1
1Graduate School of Science and Engineering, Ibaraki University, Hitachi, 316-8511, Japan.
Scientific reports
|April 7, 2024
概括
亚丁三酸盐 (ATP) 通过促进无形聚合物,防止与阿尔茨海默病相关的粉样β (Aβ) 纤维的形成. 这种水管增强了Aβ动态,为抗粉样蛋白聚合提供了潜在的治疗策略.
科学领域:
- 生物化学 生化学
- 神经科学是一个神经科学.
- 结构生物学 结构生物学
背景情况:
- 阿尔茨海默病的特点是粉样蛋白β (Aβ) 聚合成纤维状.
- Aβ可以形成纤维状和无形聚合物.
- 生物水产物可能会影响Aβ聚合途径.
研究的目的:
- 为了研究腺三酸盐 (ATP) 对Aβ聚合的影响.
- 为了确定ATP是否抑制了Aβ纤维素的形成.
- 探索ATP影响Aβ动态和结构的机制.
主要方法:
- 分散X射线闪 (DXB) 分析以评估Aβ动态.
- 提奥夫拉T光测定β-片含量.
- 原子力显微镜 (AFM) 用于可视化总体形态.
主要成果:
- 与ADP和AMP不同的是,ATP在添加后立即显著增加了Aβ动态.
- ATP促进了逐渐的β-片的形成,与缺少它时的快速形成形成形成对比.
- AFM证实ATP诱导无形聚合物 (<100nm),在4天内抑制纤维的形成.
- DXB分析表明,随着聚合物的形成,ATP的影响减弱.
结论:
- ATP充当水,诱导无形的Aβ聚合并抑制纤维的形成.
- 由ATP调解的Aβ动态增加可能是抑制纤维细胞形成的机制.
- DXB分析是评估纤维细胞形成抑制的可行方法.
相关概念视频
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183


